How can menopause be diagnosed in a woman using Depo‑Provera (150 mg intramuscular injection every 12 weeks)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Determining Menopause in Women Using Depo-Provera

Measure FSH levels while continuing Depo-Provera use, as FSH can reliably rise into the menopausal range (>25.8 mIU/mL) despite ongoing injections, and combine this with assessment of vasomotor symptoms to determine menopausal status.

Diagnostic Approach

The key challenge with Depo-Provera is that it causes amenorrhea in most users, making menstrual patterns unreliable for determining menopause. However, unlike some other hormonal contraceptives, Depo-Provera does not significantly suppress FSH levels in perimenopausal women 1, 2.

FSH Testing Strategy

  • Check FSH levels without stopping Depo-Provera - Research demonstrates that 28% of DMPA users aged 40-49 had FSH levels in the menopausal range (>25.8 mIU/mL), comparable to 32% of non-users 2
  • No significant difference exists between DMPA users and non-users in FSH detection after adjusting for age 2
  • Each additional year of age increases FSH by approximately 3 mIU/mL 2
  • FSH can be measured at any point during the 12-week injection interval 2

Clinical Assessment

Vasomotor symptoms remain useful - Studies show no difference in reporting of hot flashes between DMPA users and non-users, suggesting these symptoms can help assess menopausal status 1. The FDA label confirms that Depo-Provera inhibits gonadotropin secretion but notes that concentrations become undetectable 120-200 days post-injection 3.

Important Caveats

  • This approach is specific to DMPA (Depo-Provera) - Other progestins like NET-EN and combined oral contraceptives suppress FSH significantly more (mean FSH 11.0 and 12.5 IU/mL respectively vs 23.1 for DMPA), making FSH unreliable for those methods 1
  • Most DMPA users in studies were amenorrheic and had used the method for over 10 years, yet FSH elevation was still detectable 2

Practical Algorithm

  1. For women ≥45 years on Depo-Provera: Check serum FSH level at any time during injection cycle
  2. If FSH >25.8 mIU/mL: Consider menopausal, especially if accompanied by vasomotor symptoms
  3. If FSH <25.8 mIU/mL: Repeat in 6-12 months if clinical suspicion remains
  4. Do not discontinue Depo-Provera to check menopausal status - this is unnecessary and exposes the patient to pregnancy risk

The evidence strongly supports that FSH testing remains valid during active DMPA use, unlike with combined hormonal methods where suppression makes interpretation impossible 1, 2.

References

Related Questions

What are the diagnostic criteria and treatment options for menopause?
What are the side effects of short-term oral Medroxyprogesterone (progestin) use?
In a 57-year-old woman with low estradiol (<5 pg/mL) and progesterone (0.3 ng/mL) while taking medroxyprogesterone acetate 5 mg daily and a transdermal estradiol patch delivering 0.05 mg/24 h applied twice weekly, how should the estradiol regimen be adjusted to achieve appropriate post‑menopausal replacement levels?
In a 55-year-old postmenopausal woman with an intact uterus who experiences intolerable mood effects and breakthrough bleeding on standard oral estrogen/progestin therapy, has well‑controlled hot flashes, and osteopenia, which alternative hormone therapy regimen is most appropriate?
What is the appropriate evaluation and management for a 60-year-old woman who has begun low-dose estrogen and testosterone hormone replacement therapy (HRT) pellets with oral progesterone and now presents with slight vaginal bleeding?
Is it appropriate to prescribe retatrutide to a patient with systemic lupus erythematosus (SLE) for weight loss?
What is the typical progression and treatment options for knee tendinitis in adults, ranging from conservative measures to invasive interventions?
What is the proper method for disposing of expired sample medications, including both controlled and non‑controlled substances?
What medications should be ordered for a patient with acute dyspnea?
Is N‑acetylcysteine (NAC) effective for glucose regulation in pre‑diabetes or early type 2 diabetes, and what is the recommended dosage and monitoring?
Can tramadol and morphine be used together as part of WHO step 3 analgesic management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.